Diana Ernst, RPh

Most Recent Articles by Diana Ernst, RPh

Empagliflozin Impact on Life Expectancy Examined in T2DM Patients With CVD

Empagliflozin Impact on Life Expectancy Examined in T2DM Patients With CVD

By

For this analysis, the authors used follow-up data from all 7020 patients included in the EMPA-REG OUTCOME trial to estimate the effect of empagliflozin on all-cause mortality vs placebo over the duration of a patient's lifetime.

Gardasil 9 Approved for Use in Women and Men 27 Through 45 Years Old

Gardasil 9 Approved for Use in Women and Men 27 Through 45 Years Old

By

The approval of the expanded age range was based on data from a clinical trial which evaluated the efficacy of Gardasil (quadrivalent human papillomavirus recombinant vaccine) in 3253 women 27-45 years of age with a median duration of follow-up of 3.5 years post-dose 3.

Secretagogues Compared in Irritable Bowel Syndrome With Constipation

Secretagogues Compared in Irritable Bowel Syndrome With Constipation

By

While several secretagogues have been recently approved by the Food and Drug Administration (FDA), a lack of head-to-head trials led researchers to conduct a systematic review to compare the effectiveness of these agents in patients with IBS-C.

Imvexxy Now Available in 4mcg Dosage Strength for Dyspareunia Due to Menopause

Imvexxy Now Available in 4mcg Dosage Strength for Dyspareunia Due to Menopause

By

According to the Imvexxy prescribing information, women should generally be started at the 4mcg dosage strength with dosage adjustment guided by clinical response.

Guidelines for Managing Perimenopausal Depression Now Available

Guidelines for Managing Perimenopausal Depression Now Available

By

The 5 topics addressed by the 11-member expert panel include epidemiology, clinical presentation, therapeutic effects of antidepressants, effects of hormone therapy, and the effectiveness of other therapies (eg, psychotherapy, exercise, natural health products).

More Articles by Diana Ernst, RPh

Sign Up for Free e-newsletters